The metabolic drug sensitivity profiles generated in a panel of myeloid leukemia cell lines highlight several effective metabolic modifiers such as GSK2194069, AZD3965, and PI3K/mTOR inhibitors that could be clinically explored for a subset of myeloid leukemia patients. The gene discussed is MTOR; the disease is myeloid leukemia.